[ad_1]
RADNOR, Pa., April 29, 2022 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) has filed a securities class action lawsuit in the United States District Court for the Western District of Texas against Natera, Inc. (“Natera”) ((NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020and April 19, 2022inclusive (the “Class Period”). This action is captioned John Harvey Schneider v. Natera, Inc., et al.Case No. 1:22-cv-00398.
Important Deadline Reminder: Investors who purchased or otherwise acquired Natera common stock during the Class Period may, no later than June 27, 2022seek to be appointed as a lead plaintiff representative of the class.
CLICK HERE TO SUBMIT YOUR NATERA LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/natera-inc?utm_source=PR&utm_medium=link&utm_campaign=natera&mktm=r
TO VIEW OUR VIDEO, PLEASE CLICK HERE
TO VIEW OUR COMPLAINT, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE: June 27, 2022
CLASS PERIOD: FEBRUARY 26, 2020 through April 19, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com
NATERA’S ALLEGED MISCONDUCT
Natera, a Delaware corporation with principal executive offices in Austin, Texasoffers genetic testing in the areas of women’s health, oncology, and organ health. Among other things, the Company produces and markets a non-invasive prenatal test (NIPT), called “Panorama,” and a screening test for kidney transplant failure, called “Prospera.” Throughout the Class Period, Defendants repeatedly assured investors that Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera’s growth was driven by its superior technology and …
Full story available on Benzinga.com
[ad_2]
Source link
